Opus Biotech Communications Joins Biocom and Women in BIO
Seattle, WA , April 24, 2018 — Opus Biotech Communications, a life sciences public affairs and investor relations consultancy based in Seattle with branches in Atlanta, Newport Beach and San Francisco, today announced it has joined Biocom, a leading life sciences trade and advocacy group in California.
“Biocom represents over 1,000 research institutions and life science companies and provides one of the strongest voices in the nation for the life science industry,” Opus Principal and former first VP of Communications for the Biotechnology Industry Organization Dan Eramian stated. “We are proud to join this growing organization and look forward to contributing.”
“Industry groups like Biocom are vital to the success of startups, which are the leaders of innovation in medical research,” said Opus Principal Charles Craig, a former president of Georgia Bio and experienced biotech journalist. “Biocom has become a key driver in helping emerging California companies contribute to major advances in biotechnology.”
Additionally, the firm’s social media and marketing expert Penny Jo Welsch is now representing Opus Biotech as a member of Women in Bio. “Women in Bio is a fast-growing organization that actively supports career growth for women in the life sciences. Our Southern California chapter is an active one and I look forward to working with the members on important initiatives,” added Welsch.
About Opus Biotech Communications Services
Opus Biotech Communications is designed specifically to work with emerging life sciences companies to tell their stories of innovation, perseverance and value. We create strategies for connecting with industry news media, investors, business partners, opinion leaders, and patient groups. Our expertise is in the ability to develop compelling messages informed by decades of experience providing strategic planning in public and investor relations, CEO and company reputation management, marketing, website design, and social media. To learn more about Opus please visit our website: http://opusbiotech.com/.